Biogen (BIIB)
(Delayed Data from NSDQ)
$173.04 USD
-0.88 (-0.51%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$173.04 USD
-0.88 (-0.51%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth B Momentum A VGM
Zacks News
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 14.29% and 3.93%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: AXSM to Acquire JAZZ's Drug, IGMS Up on SNY Deal & More
by Zacks Equity Research
Acquisition and collaboration news from Axsome (AXSM) and IGM Biosciences, Inc. (IGMS), respectively, are a few key highlights from the biotech sector during the past week.
Biogen (BIIB), Ionis to End Early-Stage ALS Candidate Development
by Zacks Equity Research
Biogen (BIIB) & partner Ionis (IONS) to terminate the development of their antisense ALS candidate, as the drug failed to show any clinical benefit in an early-stage study for C9orf72-associated ALS.
Prothena (PRTA) IND Application Gets FDA Clearance for AD
by Zacks Equity Research
Prothena (PRTA) application for evaluating PRX012 for the treatment of Alzheimer's disease (AD) gets FDA clearance.
Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $211.68, marking a +0.34% move from the previous day.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $206.81, marking a -0.84% move from the previous day.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $193.77 in the latest trading session, marking a -1.97% move from the prior day.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $198.64, marking a -1.79% move from the previous day.
Denali (DNLI) Begins Frontotemporal Dementia-Granulin Study
by Zacks Equity Research
Denali (DNLI) starts an early-stage study of DNL593 for treating frontotemporal dementia (FTD) due to mutations in the granulin gene (GRN) in collaboration with Takeda.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen Inc. (BIIB) closed at $209.45, marking a -0.84% move from the previous day.
Denali (DNLI) Q4 Loss Wider Than Expected, Revenues Lag
by Zacks Equity Research
Denali (DNLI) announces wider-than-expected loss per share for fourth-quarter 2021. Revenues also miss estimates.
Ionis (IONS) Q4 Earnings & Revenues Beat Estimates, Stock Up
by Zacks Equity Research
Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics
by Zacks Equity Research
Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.
Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & More
by Zacks Equity Research
Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.
Sage Therapeutics (SAGE) Depression Drug Meets Goal, Stock Down
by Zacks Equity Research
Sage Therapeutics (SAGE) and Biogen's (BIIB) depression candidate, zuranolone given along with antidepressants improves depressive symptoms in a phase III study. Questions remain about the durability of the drug.
How Are Biotech ETFs Reacting to These Q4 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Biotech Stock Roundup: BMY, AMGN, REGN, BIIB's Q4 Earnings & More
by Zacks Equity Research
Earnings updates from Bristol-Myers (BMY), Amgen (AMGN) and others are among the few key highlights from the biotech sector during the past week.
Biogen (BIIB) Inks Agreement to Add New Biosimilar Candidate
by Zacks Equity Research
Biogen (BIIB) signs an agreement with Xbrane Biopharma for exclusive global rights to the latter's biosimilar candidate, Xcimzane, referencing UCB's arthritis drug, Cimzia.
Biogen (BIIB) Q4 Earnings Top, Stock Down on Weak 2022 View
by Zacks Equity Research
Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The stock declines on weak sales and earnings guidance for 2022.
Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 2.11% and 4.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Earnings on Feb 3: BIIB, LLY & MRK
by Zacks Equity Research
Let us take a look at three drug/biotech companies, namely, BIIB, LLY and MRK, which are gearing up for their earnings release.
AbbVie's (ABBV) Q4 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
AbbVie (ABBV) beats fourth-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares up.
Biotech Stock Roundup: GILD Q4 Earnings, REGN, MRNA's Regulatory Updates & More
by Zacks Equity Research
Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.
Is a Beat Likely for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports fourth-quarter results.
Biogen (BIIB) to Sell Biosimilar JV Stake to Samsung Biologics
by Zacks Equity Research
Biogen (BIIB) is selling its equity stake in the Samsung Bioepis joint venture to partner Samsung Biologics